## Listing of the Claims

Following is a complete listing of the claims pending in the application:

1. (Currently amended) A method of <u>decreasing IFN-y blood levels preventing</u> an increase in the blood level of IFN- $\gamma$  in a subject-at-risk of <u>with</u> an elevated IFN- $\gamma$  blood level due to-(i) administration of a therapeutic agent <u>for treating multiple sclerosis</u> or (ii) a disease condition, comprising

orally administering <u>an</u> interferon-tau (IFN $\tau$ ) <u>having greater than about 80%</u> <u>homology to ovine interferon-tau to the subject</u> at a dosage of <del>greater than 5x10<sup>8</sup></del> <u>between 6 x 10<sup>8</sup> – 5 x 10<sup>12</sup></u> Units to decrease the subject's IFN- $\gamma$  blood level relative to the IFN- $\gamma$  blood level in the absence of IFN $\tau$  administration.

- 2. (Canceled)
- 3. (Currently amended) The method of claim [[2]]  $\underline{1}$ , wherein said IFN $\tau$  has a sequence identified as SEQ ID NO:2 or SEQ ID NO:3.
- 4. (Currently amended) The method of claim 1, wherein said <u>orally</u> <u>administering is to a subject has having an elevated IFN-γ level due to <u>administration of the therapeutic agent interferon-betaan autoimmune condition, and said orally administering continues during the period of the subject's symptoms.</u></u>
  - 5-11. (Canceled)